Company Overview and News

0
Ballarpur Industries Limited - Financial Result Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500102 BALLARPUR

0
Ballarpur Industries Limited - Trading Window

2018-05-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500102 BALLARPUR

13
Deals Buzz: Fresh hurdles for Numetal, ArcelorMittal in Essar Steel sale, says report

2018-04-24 livemint
Mumbai: Mint brings to you your daily dose of top deals reported by newsrooms across the country.
ORCHIDPHAR AXB 500228 532538 UCLQF ULTRACEMCO JSWSTEEL 532215 AXBKY AXBA 524372 AXISBANK UCLQY 500102 BALLARPUR

0
Ballarpur Industries in pact to sell Malaysian unit for $310 mn

2018-04-07 freepressjournal.in
New Delhi : Ballarpur Industries on Friday said it has signed an agreement to sell its Malaysian unit Sabah Forest Industries to Pelangi Prestasi for $310 million (Rs 2,011 crore), the company said.
532670 500102 BALLARPUR RENUKA

0
Ballarpur Industries to sell Malaysian unit for $ 310 mn

2018-04-06 moneycontrol
Ballarpur Industries today said it has signed an agreement to sell its Malaysian unit Sabah Forest Industries to Pelangi Prestasi Sdn Bhd for USD 310 million (approx Rs 2,011 crore), the company said today.
500102 BALLARPUR

0
Ballarpur Industries gains 12% on sale of Sabah Forest for USD 310 million

2018-04-06 moneycontrol
Shares of Ballarpur Industries surged 12 percent intraday Friday as the company is going to sell entire assets of its Malaysian unit, Sabah Forest Industries Sdn Bhd.
500102 BALLARPUR

13
Market Live: Sensex rangebound ahead of corporate earnings; Lupin lifts Pharma index

2018-04-06 moneycontrol
12:05 pm Asia Update: Asian stocks traded mixed, as the overnight rally on Wall Street failed to translate after President Donald Trump indicated that more tariffs against China could be in the works.
IOC BINANIIND KRIINFRA MCDHOLDING JTEKY HCTHY 517506 532978 HFCL 532712 DATAMATICS 533278 532852 TTKPRESTIG RCOM 533309 522163 532281 500059 507205 DIAPOWER SONASTEER CLNDY YESBANK DALMIABHA UNITDSPR 533482 532528 532648 YYBKY 530965 JTEKF 532432 500183 BAJAJFINSV HCLTECH UQNTY TI 500102 BALLARPUR COALINDIA 520057

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...